Synthesis of polymeric nanocapsules by radical UV‐activated interface‐emulsion polymerization

A new methodology is reported that allows a better control of the synthesis of polymeric core–shell nanocapsules. These nanocapsules were made of biocompatible polymers, obtained from poly(ethylene glycol)diacrylate and poly(ethylene glycol) methyl ether methacrylate, and were used as carrier for curcumin as therapeutic agent. The impact of manufacturing factors (time of sonication, time of UV irradiation, and type of monomer) was investigated in relation to the average size of nanocapsules, their distribution, shape, composition, stability, and their capability to deliver curcumin. We successfully synthesized core–shell nanocapsules in various sizes, ranging from 80 nm to 300 nm, by acting either on the process conditions or on the composition of the monomer mixture. This wide range of sizes makes the method here proposed very promising for the production of nanocarriers. © 2016 Wiley Periodicals, Inc. J. Polym. Sci., Part A: Polym. Chem. 2016 , 54, 3357–3369     

Synthesis of S-(28a-homobetulin-28a-yl) thiophosphate,thiophosphonate, and thiophosphinate

A concise synthesis of thiophosphate, phenylthiophosphonate, and diphenylthiophosphinate esters bearing a 28a-homolupane residue is reported. The new triterpenes were obtained from the readily available 3-O-acetylichopanol by a nucleophilic substitution of the corresponding mesylate with thiocyanate ion followed by a Michaelis–Arbuzov reaction. These results open the way to new lupane-type derivatives having a thiophosphorus moiety at the lupane core as potential anticancer compounds. Additionally, the cytotoxic activities of the new homolupane compounds were evaluated in vitro.     

Development and Validation of a UHPLC UV Method for the In-Process Control of Bosentan Monohydrate Synthesis

Bosentan monohydrate (4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl) pyrimidin-4-yl]benzene-1-sulfonamide monohydrate) is a dual endothelin receptor antagonist (ERA) applied in the treatment of pulmonary arterial hypertension. To achieve effective process control of the bosentan monohydrate synthesis, it was necessary to develop a selective and not highly time-consuming method for ultra-high performance liquid chromatography (UHPLC). The method is characterized by adequate sensitivity, reproducibility and selectivity for the determination of bosentan monohydrate and related compounds from all synthetic stages. The UHPLC separation was carried out by reversed phase chromatography on the Acquity BEH C18 column (100 mm × 2.1 mm, 1.7 µm) with a mobile phase composed of solvent A (0.1 %, v/v, acetic acid in water) and solvent B (methanol), in the gradient mode at the flow rate of 0.4 mL min⁻¹. Limits of detection and quantification for the compounds were ≤0.1 µg mL⁻¹ and 0.3 µg mL⁻¹, respectively. The linearity for all related compounds was investigated as in the range for the active pharmaceutical ingredient (API) and as in the range for the in-process control. The developed method was validated according to the current guidelines, proving the suitability of the method for its intended purpose.